Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF)...
Enregistré dans:
Auteur principal: | Jadwiga Nessler |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Termedia Publishing House
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7df11093d00449928650f3e7ff95d42c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
par: Avgerinos I, et autres
Publié: (2019) -
Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
par: Olga Yuryevna Sukhareva, et autres
Publié: (2016) -
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
par: Kuecker CM, et autres
Publié: (2016) -
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
par: Steffen Pabel, et autres
Publié: (2021) -
Left ventricular systolic dysfunction among nocturnal myocardial infarctions
par: A Ghaemian, et autres
Publié: (2004)